These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18454047)

  • 21. 14-3-3sigma-dependent resistance to cisplatin.
    Han Z; Dimas K; Tian X; Wang Y; Hemmi H; Yamada K; Kato N; Pantazis P; Ramanujam RJ; Anant S; Wyche JH; Houchen CW
    Anticancer Res; 2009 Jun; 29(6):2009-14. PubMed ID: 19528459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cytotoxicity of high-linear energy transfer radiation is reinforced by oxaliplatin in human glioblastoma cells.
    Benzina S; Debomy F; Bergerat JP; Denis JM; Gueulette J; Dufour P; Bischoff P
    Cancer Lett; 2007 Aug; 254(1):54-62. PubMed ID: 17383816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin.
    Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM
    Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
    Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
    Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin.
    Lukyanova NY; Rusetskya NV; Tregubova NA; Chekhun VF
    Exp Oncol; 2009 Jun; 31(2):87-91. PubMed ID: 19550397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.
    Ganjavi H; Gee M; Narendran A; Parkinson N; Krishnamoorthy M; Freedman MH; Malkin D
    Cancer Gene Ther; 2006 Apr; 13(4):415-9. PubMed ID: 16211088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
    Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
    J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
    Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
    Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers.
    Maurer BJ; Ihnat MA; Morgan C; Pullman J; O'Brien C; Johnson SW; Rasey JS; Cornwell MM
    Mol Pharmacol; 1999 May; 55(5):938-47. PubMed ID: 10220573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
    Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
    ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides.
    Datta K; Shah P; Srivastava T; Mathur SG; Chattopadhyay P; Sinha S
    Cancer Gene Ther; 2004 Aug; 11(8):525-31. PubMed ID: 15167899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
    Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
    Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
    Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
    Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
    Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
    Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.